No Data
No Data
Biomedical sector showing strong performance, Pharmaron (03759) rose by 14.97%. Institutions believe there is still room for further increase in sector valuation.
Golden Finance News | The biomedical sector is showing strong performance, with Pharmaron (03759) up 14.97%, Remegen (09995) up 13.59%, Tigermed (03347) up 12.58%, Wuxi Bio (02269) up 11.79%, Wuxi Apptec (02359) up 10.56%, Akeso (09926) up 8.92%. In terms of news, Guoyuan International believes that the main reason for the outperformance of the pharmaceutical sector in this round of large gains is due to the deeper decline in the pharmaceutical sector in the previous period (as of September 23, MSCI China Meheco Group Index has fallen 23% year-to-date), sector.
Recent Uptick Might Appease RemeGen Co., Ltd. (HKG:9995) Institutional Owners After Losing 67% Over the Past Year
REMEGEN: 2024 Interim Report
Market Chatter: RemeGen Denies Rumors of Mass Layoffs; Shares Up 4%
Significant layoffs? Remegen responds: It is a normal business optimization. The recently adapted indication for Taitsip will be applied for listing.
①Regarding the online rumors of layoffs, the secretary of the board of directors of Remegen stated that the company has been sorting out its business since last year, and the optimization of positions and personnel is based on work needs, without a rigid proportion; ②The other party revealed that the severe myasthenia gravis indication of the targeted drug Taituxip is expected to apply for market approval soon. However, Taituxip is facing multiple competitions in the market.
Hong Kong stocks closed (09.16) | The Hang Seng Index rose 0.31%, and shares of innovative drug concept stocks led the gains. Yimingang Corporation (01541) doubled in value in three days.
Affected by multiple bearish news over the weekend, the Hong Kong stock market opened lower in the morning, but then maintained a volatile rise throughout the day. As of the close, the Hang Seng Index rose by 0.31% or 53.03 points, to 17422.12 points.
No Data
No Data